Author

Teng Teng

Tango Therapeutics (United States)

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1

Frequent Co-Authors

Alan HuangiD· 1 shared Ashley H. ChoiiD· 1 shared Binzhang SheniD· 1 shared Charlotte B. PrattiD· 1 shared Chengyin MiniD· 1 shared Eden N. Gordon· 1 shared Hannah StoweiD· 1 shared Helena N. Jenkins· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alan HuangORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Tumor suppressor collateral damage screens reveal mRNA homeostasis protein HBS1L as a novel vulnerability in ch9p21 driven FOCAD deleted cancer

Hongxiang Zhang, Matthew R. Tonini, Lauren Catherine M. Martires, Helena N. Jenkins, Charlotte B. Pratt, Eden N. Gordon, Shan-Chuan Zhao, Ashley H. Choi, Samuel R. Meier, Tenzing Khendu, Shangtao Liu, Binzhang Shen, Hannah Stowe, Katerina Pashiardis, Xuewen Pan, , Teng Teng

The paper identifies HBS1L as a synthetic lethal target in FOCAD-deleted cancer through combinatorial CRISPR screens and validates its dependency via genetic manipulation and in vivo experiments.

Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · Oct 15, 2025Peer-reviewedCancer Biology